Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077779 · ClinicalTrials.gov registry record · Phase 3
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
- 20
- Study locations
NCT00077779 is a Phase 3 study of Crohn's Disease that has completed, run by Abbott. The registered enrollment target is 854 participants, below the 2,406-participant average among 104 other Crohn's Disease trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00077779, a Phase 3 study of Crohn's Disease, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
Conditions Studied
Interventions
- DRUG Adalimumab
Study Locations (20)
Florida
- Clinical Research of West Florida, Inc. - Clearwater
- V.A. Medical Center - Gainsville
- Mark Lamet, MD - Hollywood
- Gastroenterology Consultants - Ormond Beach
California
- Thornton Hospital Reumatology Division - La Jolla
- UCSF San Francisco General Hospital - San Francisco
- Cal-West, Inc. - San Francisco
Illinois
- Northwest Gastroenterology - Arlington Heights
- Northwestern University - Chicago
- The University of Chicago - Chicago
Maryland
- Maryland Clinical Trials - Annapolis
- Chevy Chase Clinical Research - Chevy Chase
- Capital Gastroenterology Consultants, P.A. - Silver Spring
Indiana
- Indianapolis Gastroenterology Research Foundation - Indianapolis
- St. Vincent Hospital: Research Department - Indianapolis
Colorado
- Western States Clinical Research - Arvada
Connecticut
- Gastroenterology Associates of Fairfield County - Bridgeport
Louisiana
- Drug Research Services, Inc. - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2003-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077779
The ClinicalTrials.gov registry entry for NCT00077779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 854 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,406-participant average among 104 other Crohn's Disease trials with a reported enrollment target (65% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab is the first listed.
NCT00077779 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00077779 about?
NCT00077779 is a clinical study titled "Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease". The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
What is the current status of trial NCT00077779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2003-07.
What conditions does trial NCT00077779 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00077779?
The interventions under investigation include: Adalimumab (DRUG).
Who is sponsoring clinical trial NCT00077779?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00077779 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.